Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Marker Therapeutics (MRKR) Interest & Investment Income (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Interest & Investment Income for 8 consecutive years, with $138064.0 as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 50.59% to $138064.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $502324.0, a 11.03% decrease, with the full-year FY2024 number at $437010.0, down 18.95% from a year prior.
  • Interest & Investment Income was $138064.0 for Q3 2025 at Marker Therapeutics, up from $128025.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $218085.0 in Q3 2023 to a low of $791.0 in Q3 2021.
  • A 5-year average of $87289.9 and a median of $91681.0 in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: plummeted 98.79% in 2021, then soared 12510.62% in 2022.
  • Marker Therapeutics' Interest & Investment Income stood at $969.0 in 2021, then skyrocketed by 11191.12% to $109411.0 in 2022, then soared by 84.02% to $201339.0 in 2023, then tumbled by 63.37% to $73746.0 in 2024, then soared by 87.22% to $138064.0 in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Interest & Investment Income are $138064.0 (Q3 2025), $128025.0 (Q2 2025), and $162489.0 (Q1 2025).